Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors
- Registration Number
- NCT06362590
- Lead Sponsor
- Seagen Inc.
- Brief Summary
The purpose of this study is to provide the option of Ladiratuzumab Vedotin treatment to eligible patients in studies SGNLVA-005.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- AVAILABLE
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Read More
Exclusion Criteria
Read More
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method